Junshi PD-1 Granted US Orphan Designation for Small Cell Lung Cancer
publication date: Apr 14, 2022
Shanghai Junshi Bio was granted US Orphan Drug Designation for toripalimab, its PD-1 inhibitor, to treat small cell lung cancer. Immunotherapies have not been particularly effective in SCLC because the disease has low expression of PD-L1 and low levels of tumor infiltrating immune cells. Junshi believes that toripalimab is effective in low PD-1 cancers. Toripalimab is in a US Phase III trial as a first line therapy for extensive stage SCLC. In 2021, Junshi partnered US-Canada rights for toripalimab with Coherus BioSciences of Redwood City, CA in a $1.1 billion agreement. More details...
Stock Symbols: (HK: 1877; SHA: 688180)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.